New Medicines for Animals:

1
Dr Christianne Bruschke
New Medicines for Animals A Growing Global Need
IFAH Europe Conference The Animal Health
Industry- an essential Partner for Global
Health Brussels 28 June 2006
2
World Organisation for Animal Health (OIE)

• Founded in 1924
• 167 Member Countries
• Headquarters in Paris
• 5 Permanent Regional Representatives
• 2 Subregional Offices
• 5 Regional Commissions
• An intergovernmental organisation
• Mandate to improve Animal Health worldwide

3
OIE Objectives

• World zoosanitary information
• International solidarity in control of animal
  diseases
• Health standards for international trade
• Provide a better guarantee of the safety of food
  of animal origin

4
Trends in demand for livestock products

• Expected increase in per caput consumption
  between now and 2100
• Meat factor 2.5, developing countries factor 5
• Eggs factor 3, developing countries factor 8
• Milk factor 2, developing countries factor 5

5
Scenario of total consumption of Livestock
products
6
Trends in growth of global livestock sector

• Strong increase in global numbers of animals
• Regional differences in increase of beef, pork
  and poultry production based on cultural,
  religious or nutritional preferences
• Differences between developing and developed
  countries
• Strong increase of industrial livestock farming
  systems

7
Animal diseases economic and social consequences

• High economic and social negative consequences
• Loss of livelihoods
• Increase of poverty

8
Minimize Threat of Emerging Animal Diseases

• Early warning systems
• Early detection
• Awareness
• High quality Veterinary Services
• Rapid and transparent notification
• Appropriate national chain of command

9
Minimize Threat of Emerging Animal Diseases

• Rapid response
• rapid confirmation of suspects
• confinement and humane stamping out
• use of vaccination when available and if
  appropriate
• Governance, legislation, policies and resources,
  in compliance with OIE international standards

10
Veterinary Vaccine Market

• Market is as big as human market but much more
  divers (160 versus 30 vaccines)
• Market is heterogenous
• Countries
• Species
• conditions

11
Vaccine sells per region (Wood Mackenzie 2002)
30
25
20
15
10
5
0
North
West
Far East
Latin
East
Rest of
America
Europe
America
Europe
world
12
OIE standards and guidelines
13
Terrestrial Animal Health Code

• assure the sanitary safety of international trade
• health measures to be used by the veterinary
  authorities of importing and exporting countries
• avoid the transfer of agents pathogenic for
  animals or humans
• avoiding unjustified sanitary barriers.

14
OIE listed Diseases
15
The Terrestrial Manual The book is a mine of
information for all dealing with veterinary
diseases... SGM Quarterly

• contribute to the international harmonisation of
  methods for the surveillance and control of the
  most important animal diseases.
• Standards and alternatives for laboratory
  diagnostic tests
• Standards for the production and control of
  biological products (principally vaccines) for
  veterinary use across the globe.

16
A survey of Vaccines for listed diseases in OIE
member Countries (2002)

• Large number of vaccines for FMD, CSF and NDV
• Limited number of vaccines for AHS, Bleu Tongue,
  CBPP, HPAI, LSD, PPR, RVF, RP, S/G Pox, SVD and
  VS
• An outbreak of any of these diseases will have
  very serious consequences

17
Major Zoonotic Threats (OIE 2004)

• Vector-Borne diseases WNV, RVF, Leishmaniasis
• Bacterial Zoonotic Diseases Leptospirosis,
  Borreliosis, Salmonellosis
• Emerging Viral Zoonotic Pathogens Hanta, HFS
• Tuberculosis, Rabies

18
New Medicines Global Perspective

• Global public good to address major animal
  diseases world wide
• Importance of livestock to developing countries
• Grow and intensification of livestock in
  developing world
• Animal diseases have direct and major impacts on
  food security and poverty alleviation

19
General barriers in vaccine, pharmaceuticals and
diagnostic development

• More basic research necessary to be innovative
• Non vaccination policy in Europe
• Development of new medicines is very expensive
• Patent issues patents are essential
• Return on investment big market is essential
• Reluctance in development / use of recombinant
  medicines

20
Orphan Diseases

• Vaccine development is expensive
• Small markets and low return on investment
• Responsibility of Governments and international
  organisations to invest in the development
• Availability of these vaccines is a global public
  good

21
Desired Developments

• Develop partnerships public private
• Networks human animal interface
• Stimulate innovation (harmonise guidelines for
  GMOS)
• Make new vaccines widely available also
  developing countries
• More basic research from trial and error to
  rational vaccine design
• Build a robust regulatory process also with
  regard to emerging diseases.

22
(No Transcript)
23
World organisation for animal health
12 rue de Prony 75017 Paris, France Tel 33 (0)1
44 15 18 88 Fax [phone] Email
oie_at_oie.int http//www.oie.int